The Expert Committee recommended the inclusion of fluoxetine on the EML for the new indications of use in generalized anxiety disorder, panic disorder, and social anxiety disorder. Listing is recommended with a square box specifying citalopram, escitalopram, fluvoxamine, paroxetine, and sertraline as therapeutic alternatives. The Committee considered that the evidence presented in the application supported the use of fluoxetine and the proposed alternative selective serotonin reuptake inhibitors (SSRIs) for these indications as they were shown to be more effective than placebo in reducing anxiety symptoms and have a well-known and acceptable safety profile.